Insider · CIK 0001816194

Gall Matthew

Reports to the SEC for 3 companies · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001816194

Forms 4 and 5

Insider transactions

24 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-05-01	TNGXTango Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+40K sh	—	—	40,000
2026-05-01	TNGXTango Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+240K sh	—	—	240,000
2026-03-19	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+95K sh	—	—	95,000
2025-11-03	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+235K sh	—	—	235,000
2025-08-29	iTeos Therapeutics, Inc.U Disposition from Tender	Chief Financial Officer	UDisposition from Tender	−89.4K sh	—	—	0
2025-08-29	iTeos Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−9,063 sh	—	—	0
2025-08-29	iTeos Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−136K sh	—	—	0
2025-08-29	iTeos Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−42.4K sh	—	—	0
2025-08-29	iTeos Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−8,123 sh	—	—	0
2025-08-29	iTeos Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−252K sh	—	—	0
2025-03-07	iTeos Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+24K sh	—	—	89,429
2025-03-07	iTeos Therapeutics, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+145K sh	—	—	145,000
2024-11-19	iTeos Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+5,000 sh	$7.73	+$38.6K	65,429
2024-03-07	iTeos Therapeutics, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+163K sh	—	—	163,200
2023-12-05	iTeos Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+41K sh	—	—	60,429
2023-10-12	iTeos Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+5,000 sh	$8.37	+$41.8K	19,429
2023-03-09	iTeos Therapeutics, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+130K sh	—	—	130,000
2022-03-11	iTeos Therapeutics, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+85K sh	—	—	85,000
2021-12-27	iTeos Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−5,000 sh	$46.45	−$232K	14,429
2021-10-11	iTeos Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+14.4K sh	$6.16	+$88.9K	19,429
2021-10-11	iTeos Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−14.4K sh	—	—	42,388
2021-06-24	iTeos Therapeutics, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+24K sh	—	—	24,000
2021-06-16	iTeos Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+5,000 sh	$26.09	+$130K	5,000
2021-03-01	iTeos Therapeutics, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+72K sh	—	—	72,000

Recent filings

Accepted (ET)
May 54
Gall Matthew0001193125-26-207094
SEC(opens sec.gov)
Mar 204
Gall Matthew0001193125-26-117617
SEC(opens sec.gov)
Nov 34
Gall Matthew0001193125-25-262831
SEC(opens sec.gov)
Aug 294
Gall Matthew0000950170-25-112236
SEC(opens sec.gov)
Mar 114
Gall Matthew0000950170-25-037512
SEC(opens sec.gov)
Nov 194
Gall Matthew0000950170-24-128956
SEC(opens sec.gov)
Mar 84
Gall Matthew0000950170-24-028862
SEC(opens sec.gov)
Dec 74
Gall Matthew0000950170-23-068901
SEC(opens sec.gov)
Oct 124
Gall Matthew0001209191-23-052709
SEC(opens sec.gov)
Mar 104
Gall Matthew0001209191-23-018015
SEC(opens sec.gov)
Mar 144
Gall Matthew0001209191-22-018668
SEC(opens sec.gov)
Dec 284
Gall Matthew0001209191-21-071435
SEC(opens sec.gov)
Oct 124
Gall Matthew0001209191-21-060297
SEC(opens sec.gov)

Companies

Address

C/O TANGO THERAPEUTICS, INC. 201 BROOKLINE AVE., SUITE 901

BOSTON, MA, 02215